ERBB2 and breast cancer: The most prevalent variations identified in our Chinese BC cohort was TP53 mutation (54.5%), followed by mutations in PIK3CA (39.5%), ERBB2 (30.2%), CDK12 (22.9%), and GATA3 (18.3%).